Αποτελέσματα Αναζήτησης
12 Οκτ 2020 · Inherent in the quest for new anticoagulants is minimizing the risk of bleeding while on therapy. The challenge in differentiating hemostasis from thrombosis is that they reflect different outcomes originating from the same processes.
4 Μαρ 2020 · Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge is the side...
19 Μαρ 2015 · The non-vitamin K antagonist oral anticoagulants are already replacing low-molecular-weight heparin for thromboprophylaxis in patients undergoing elective hip or knee arthroplasty and replacing warfarin for stroke prevention in patients with atrial fibrillation and treatment of venous thromboembolism.
12 Οκτ 2020 · With the goal of developing a new class of anticoagulants associated with a lower risk of bleeding than currently available agents, dozens of drugs targeting the contact system are now in development.
18 Απρ 2016 · The following are 10 key points to remember from this review on the use of new anticoagulant (NOAC, also known as direct oral anticoagulants) agents for treatment of venous thromboembolism (VTE): VTE is a common disease with a high risk for recurrence, death, and late sequela. One-year case fatality rates approach 23%.
25 Φεβ 2015 · This review discusses the new anticoagulants such as dabigatran, edoxaban, rivaroxaban, and apixaban, and provides practical and easy-to-use algorithms for application in the clinical routine specially focused on AF prophylaxis.
29 Απρ 2016 · Four DOACs are now licensed: dabigatran, which inhibits thrombin 7; and rivaroxaban, 8 apixaban, and edoxaban, 9, 10 which inhibit factor Xa.
